Barosi G - Search Results

1

Inadequate erythropoietin response to anemia: definition and clinical relevance.

Barosi G. Barosi G. Ann Hematol. 1994 May;68(5):215-23. doi: 10.1007/BF01737420. Ann Hematol. 1994. PMID: 8018762 Review.

2

Guidelines for the use of recombinant human erythropoietin.

Barosi G, Cazzola M, De Vincentiis A, Grossi A, Tura S. Barosi G, et al. Haematologica. 1994 Nov-Dec;79(6):526-33. Haematologica. 1994. PMID: 7896210 No abstract available.

3

Postpheochromocytoma erythropoietin-dependent erythrocytosis. A postischemic mechanism?

Bosio M, Barosi G. Bosio M, et al. Among authors: barosi g. Am J Pediatr Hematol Oncol. 1994 Nov;16(4):365-7. Am J Pediatr Hematol Oncol. 1994. PMID: 7978058

4

Control of erythropoietin production in man.

Barosi G. Barosi G. Haematologica. 1993 Mar-Apr;78(2):77-9. Haematologica. 1993. PMID: 8349195 No abstract available.

5

Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies.

Mesa RA, Kiladjian JJ, Verstovsek S, Al-Ali HK, Gotlib J, Gisslinger H, Levy R, Siulnik A, Gupta V, Khan M, DiPersio JF, McQuitty M, Catalano JV, Hunter DS, Knoops L, Deininger M, Cervantes F, Miller C, Vannucchi AM, Silver RT, Barbui T, Talpaz M, Barosi G, Winton EF, Mendeson E, Harvey JH Jr, Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Sun W, Sandor V, Kantarjian HM, Harrison C. Mesa RA, et al. Among authors: barosi g. Haematologica. 2014 Feb;99(2):292-8. doi: 10.3324/haematol.2013.087650. Epub 2013 Aug 2. Haematologica. 2014. PMID: 23911705 Free PMC article. Clinical Trial.

6

Setting Appropriate Goals for the Next Generation of Clinical Trials in Myelofibrosis.

Barosi G. Barosi G. Curr Hematol Malig Rep. 2015 Dec;10(4):362-9. doi: 10.1007/s11899-015-0281-2. Curr Hematol Malig Rep. 2015. PMID: 26277615 Review.

7

Therapeutic approaches in myelofibrosis.

Barosi G, Rosti V, Vannucchi AM. Barosi G, et al. Expert Opin Pharmacother. 2011 Jul;12(10):1597-611. doi: 10.1517/14656566.2011.568939. Epub 2011 Apr 4. Expert Opin Pharmacother. 2011. PMID: 21457082 Review.

8

Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: a phase II trial.

Marchetti M, Barosi G, Balestri F, Viarengo G, Gentili S, Barulli S, Demory JL, Ilariucci F, Volpe A, Bordessoule D, Grossi A, Le Bousse-Kerdiles MC, Caenazzo A, Pecci A, Falcone A, Broccia G, Bendotti C, Bauduer F, Buccisano F, Dupriez B. Marchetti M, et al. Among authors: barosi g. J Clin Oncol. 2004 Feb 1;22(3):424-31. doi: 10.1200/JCO.2004.08.160. J Clin Oncol. 2004. PMID: 14752066 Clinical Trial.

9

Clinical and economic impact of epoetins in cancer care.

Marchetti M, Barosi G. Marchetti M, et al. Among authors: barosi g. Pharmacoeconomics. 2004;22(16):1029-45. doi: 10.2165/00019053-200422160-00001. Pharmacoeconomics. 2004. PMID: 15524492 Review.

10

Involvement of TGFβ1 in autocrine regulation of proplatelet formation in healthy subjects and patients with primary myelofibrosis.

Badalucco S, Di Buduo CA, Campanelli R, Pallotta I, Catarsi P, Rosti V, Kaplan DL, Barosi G, Massa M, Balduini A. Badalucco S, et al. Among authors: barosi g. Haematologica. 2013 Apr;98(4):514-7. doi: 10.3324/haematol.2012.076752. Epub 2013 Feb 12. Haematologica. 2013. PMID: 23403314 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results